Bayer reports phase I results for prostate cancer therapy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/25/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
Bayer earnings preview: Recent focus on asundexian momentum ahead of Q4 results
March 3, 2026 6:00 PM ESTBayer AG (OTC: BAYRY) reports fourth-quarter and full-year 2025 results on Wednesday, with analysts more recently focusing on the companys litigation overhang and Asundexian stroke data.
Consensus forecasts point to sales of 11.34 billion for Q4 2025 and 45.48 billion for the full year. Net income is expected to remain negative for 2025, with analysts on average forecasting a 223 million... More
